17 min listen
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
ratings:
Length:
11 minutes
Released:
Apr 8, 2024
Format:
Podcast episode
Description
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Released:
Apr 8, 2024
Format:
Podcast episode
Titles in the series (100)
The Lancet Oncology: October 01, 2008 by The Lancet Oncology in conversation with